Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose-Escalation Study of ABBV-368 in Advanced Solid Tumors (Japan)
jRCT2080224901Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of revdofilimab in Nonhematologic neoplasms, sponsored by AbbVie Inc. Primary endpoints: Safety and tolerability of ABBV-368 and Pharmacokinetics of ABBV-368. Started Oct 2019; status: completed.
02
Drugs
revdofilimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080224901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224901.